Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia

Elisenda Climent1, Sofia Pérez-Calahorra2, Victoria Marco-Benedi2, Nuria Plana3, Rosa Sánchez4, Emilio Ros5, Juan F. Acsaco6, Jose Puzo7, Fátima Almagro8, Carlos Lahoz9, Fernando Civeira2 & Juan Pedro-Botet1

Patients with heterozygous familial hypercholesterolemia (HeFH) have been reported to be less vulnerable to type 2 diabetes mellitus (T2DM), although the mechanism is unknown. The aims of the present study were to assess the effects of low density lipoprotein (LDL) cholesterol concentration and the presence of FH-causing mutations on T2DM prevalence in HeFH. Data were collected from the Dyslipidemia Registry of the Spanish Arteriosclerosis Society. Inclusion criteria were definite or probable HeFH in patients aged ≥18 years. T2DM prevalence in HeFH patients was compared with data of the general population. 1732 patients were included. The prevalence of T2DM was lower in patients with HeFH compared with the general population (5.94% vs 9.44%; OR: 0.606, 95% CI 0.486–0.755, p < 0.001). Risk factors for developing T2DM were male sex, age, body mass index, hypertension, baseline triglyceride levels and years on statin therapy. The prevalence of T2DM in HeFH patients was 40% lower than that observed in the general population. Gene mutations and LDL cholesterol concentrations were not risk factors associated with the prevalence of T2DM in patients with HeFH. The prevalence of T2DM in patients with HeFH was 40% lower than in the general population matched for age and sex.

Heterozygous familial hypercholesterolemia (HeFH), the most frequent monogenic disorder of human metabolism caused by some mutations in the genes that encode for the low-density lipoprotein (LDL) receptor, apolipoprotein (apo) B, proprotein convertase subtilisin/kexin-type 9 (PCSK9) or apo E1, 2, entails an increased risk of premature cardiovascular disease.

Patients with HeFH had been reported to be less vulnerable to type 2 diabetes mellitus (T2DM) compared to the general population3. More recently, Besseling et al. in a cross-sectional study found the prevalence of T2DM to be 50% lower in HeFH patients compared to unaffected relatives4. One of the mechanisms suggested to explain

1Lipid and Vascular Unit, Department of Endocrinology and Nutrition, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain. 2Lipid Unit. Hospital Universitario Miguel Servet, IIS Aragón, Universidad de Zaragoza, Zaragoza, Spain. 3Unitat de Medicina Vascular i Metabolisme, Hospital Universitari Sant Joan, Institut d’Investigació Sanitaria Pere Virgili (IISPV), Reus, Tarragona, Spain. 4Lipid Unit, Servicio de Endocrinología y Nutrición, Hospital Universitario Insular de Gran Canarias, Instituto Universitario de Investigaciones Biomédicas y Sanitarias de la Universidad de Las Palmas de Gran Canarias, Las Palmas, Spain. 5Lipid Clinic, Endocrinology and Nutrition Service, Institut d’Investigacions Biomèdiques August Pi Sunyer, Hospital Clínic, Barcelona and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. 6Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario, Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Universitat de Valencia, Valencia, Spain. 7Lipid Unit. Hospital San Jorge, Huesca, Spain. 8Lipid Unit, Hospital Donostia, San Sebastián, Spain. 9Atherosclerosis Unit, Internal Medicine Department, Hospital Carlos III, Madrid, Spain. Correspondence and requests for materials should be addressed to J.P.-B. (email: 86620@parcadesalutmar.cat)
this finding lies in potential decreased cholesterol uptake by pancreatic β cells in HeFH. This lower T2DM risk contrasts with the fact that most HeFH patients are treated with high doses of potent statins which exert a dose-dependent diabetogenic effect. The molecular pathways that may be involved in the resistance to T2DM in HeFH and the statin-related T2DM have not been studied in depth in humans. Suggested mechanisms include defects in insulin signaling, pancreatic β-cell function and reduced glucose uptake in adipocytes throughout the glucose transporter-4 (GLUT4) pathway. The potential effect of LDLR mutations or LDL cholesterol concentrations on these anti-diabetogenic and pro-diabetogenic effects of HeFH and statins, respectively, are unknown.

The cholesterol-lowering effect of statin therapy is mainly due to the inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase, a key enzyme in cholesterol synthesis that induces a reduction in intracellular cholesterol content and a subsequent increase in LDL receptor expression in different tissues and the promotion of transmembrane cholesterol transport, the primary altered mechanism in FH. If intracellular cholesterol uptake via the LDL receptor is involved in the pathogenesis of T2DM, then it would explain the hypothetical protection from diabetes in HeFH patients, but only in those with genetic defects affecting LDL receptor uptake, in contrast to the hypothesis that the protection would be dependent on the high plasma LDL-cholesterol concentrations observed in HeFH. Hence, the aims of the present study were to assess the prevalence of T2DM in HeFH patients of the Dyslipidemia Registry of the Spanish Arteriosclerosis Society, and evaluate the impact of mutations in the LDLR, APOB and PCSK9 genes, baseline LDL cholesterol concentration and duration of statin treatment on T2DM prevalence in this population.

Research Design and Methods

Study population. The Dyslipidemia Registry of the Spanish Arteriosclerosis Society was created at the end of 2013 as an active on-line registry in which 50 certified Lipid Units distributed throughout Spain enter cases with different primary hyperlipidemias. These Lipid Units are the centers in the Spanish National Health Service to which most cases of primary hyperlipidemias are referred for diagnosis and treatment. The registry was approved by a central ethics committee to include anonymous clinical data (Comité Ético de Investigación Clínica de Aragón, Zaragoza, Spain) in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. Patients did not have to complete an informed consent form as the data were obtained from an official national registry. Minimum data for the inclusion of cases in the registry are: age, sex, smoking status, personal history of hypertension, diabetes and cardiovascular disease with age at the first event, body mass index (BMI), waist circumference, total cholesterol, LDL cholesterol, triglycerides and high-density lipoprotein (HDL) cholesterol without lipid-lowering treatment, and clinical diagnosis. Cardiovascular disease in the registry is defined as: coronary heart disease (myocardial infarction, acute coronary syndrome with stenosis >50% of a main coronary artery and coronary revascularization), stroke (ischemic and hemorrhagic), aortic aneurysm and lower limb ischemia (intermittent claudication with ankle/brachial index <0.90 or revascularization of lower limb arteries). T2DM is defined in the presence of fasting blood glucose >125 mg/dL or use of blood glucose-lowering drugs.

Inclusion criteria in the present study were: complete minimum data for the registry, plus information on family history of hypercholesterolemia and premature cardiovascular disease; personal history of tendon xanthomas and presence of arcus cornealis before the age of 45; genetic study of LDLR, APOB and PCSK9 genes; age at statin onset; and age at T2DM diagnosis. Only subjects with probable (6–8 points) or definite (>8 points) HeFH according to the Dutch Lipid Clinic Network criteria and age ≥18 years were finally included. The diagnosis of homoygous FH (HoFH) was an exclusion criterion.

Of the 2,475 cases with the clinical diagnosis of genetic hypercholesterolemia included in the registry, 1,732 diagnosed of HeFH with Dutch Lipid Clinic Network (DLCN) criteria ≥6 points and complete data were finally included. Reasons for exclusion from the analysis were HoFH or DLCN <6 points and lack of data on genetic analysis, among others.

The prevalence of T2DM was analyzed according to a probable or definite diagnosis of HeFH, the presence of a genetic mutation or the gene involved. Furthermore, T2DM prevalence in HeFH patients was compared with data of the general population matched for age and sex from the Di@bet.es Study. The Di@bet.es Study is a national, cross-sectional, population-based survey conducted in 2009–10 in a representative random sample of the Spanish population.

Blood specimens were collected after an overnight (>10 h) fast and processed for laboratory analyses the same day. Serum total cholesterol, triglycerides and HDL cholesterol levels were measured locally using enzymatic methods. Serum LDL cholesterol concentration was calculated using the Friedewald formula.

DNA was isolated from whole blood using standard methods and screening for LDLR, APOB and PCSK9 mutations was carried out using the Lipochip Platform (Progenika Biopharma S. A., Bilbao, Spain). The platform consists of two consecutive steps: the first is LIPOchip® microarrray analysis for the detection of the most frequent Spanish point mutations in the LDLR gene and in the APOB exon 26, as well as CNVs in LDLR. When the LIPOchip® microarray yielded a negative result (no mutation is found), the LDLR, APOB (binding domain) and PCSK9 gene coding sequences, exon-intron boundaries, and short proximal intronic sequences were sequenced with a GS Junior system (Roche Diagnostics Corporation, Basel, Switzerland).

Statistical analysis. Data were expressed as mean ± standard deviation for parametric variables and as median ± interquartile range for non-parametric quantitative variables. The Mann-Whitney U test was used for comparison between groups; quantitative variables were shown as % (n) and chi-square test was applied for qualitative variables between groups. Logistic regression analysis including sex, age, BMI, smoking status, hypertension, tendon xanthomas, baseline LDL and HDL cholesterol and triglyceride concentrations, genetic diagnosis and statin therapy duration was applied to evaluate factors independently associated with the presence of T2DM in HeFH patients. A two-sided p value < 0.05 was considered statistically significant. Statistical analysis was calculated with SPSS (version 19.0 for Windows; SPSS, Chicago, IL).
Results

One thousand, seven hundred and thirty-two patients were included (354 with probable and 1,378 with definite HeFH) (Fig. 1). No differences were found between groups in terms of gender, cardiovascular disease prevalence and HDL cholesterol concentration. As expected because of the DLCN definition, total cholesterol and LDL cholesterol concentrations were higher, and the presence of tendon xanthomas more common in definite than in probable HeFH. In contrast, the prevalence of T2DM and variables associated with the metabolic syndrome and diabetes i.e. age, BMI, waist circumference, triglycerides, glucose and prevalence of hypertension were higher in the probable HeFH group than in definite HeFH. Subjects with definite HeFH had begun statin therapy 7 years earlier than probable HeFH (Table 1).

Table 1. Demographic and clinical characteristics of heterozygous familial hypercholesterolemia patients. Values are expressed as median (interquartile range) for continuous variables and percentage (n) for categorical variables. HDL denotes high-density lipoprotein; LDL, low-density lipoprotein.

Figure 1. Study flow diagram. HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; DLCN, Dutch Lipid Clinic Network.
Second, in the present study, no differences were observed in the prevalence of T2DM when patients were separated into different subgroups according to LDL-cholesterol concentrations (Fig. 2).

Risk factors for HeFH patients developing T2DM are presented in Table 4 for the whole HeFH group and in Table 5 for patients with a positive genetic diagnosis. Male sex, BMI, hypertension and on statin therapy were independently associated with the presence of T2DM in both groups. These risk factors could account for up to 26% of the variability in presenting T2DM (Table 4). Other factors such as age, BMI, smoking status, xanthomas, baseline LDL, HDL cholesterol and triglyceride concentrations did not reach statistical significance.

Finally, different regression models were applied to identify the association of a pathogenic mutation in LDLR, APOB or PCSK9 in the presence of T2DM. None of the models with different adjustments showed any significant association of a positive genetic diagnosis with T2DM (Table 6).

### Discussion

The prevalence of T2DM in HeFH patients in the present study was 5.9%, lower than the known 9.4% prevalence in the age and sex-adjusted Spanish population. In a Dutch cohort, the prevalence of T2DM in HeFH patients was 1.75% compared to 2.93% in unaffected relatives. This may be partially explained by younger age in the Dutch HeFH cohort, more than one decade, compared to our population and the different criteria used in the diagnosis of T2DM between studies, only auto-reported in the Dutch cohort. Nevertheless, our study confirms the Dutch results in a completely different population, showing that HeFH subjects present an approximately 50% lower T2DM risk than the general population. This T2DM protection has been questioned in favor of a role for LDL overload lowered insulin secretion and diet-induced hypercholesterolemia also reduced insulin secretion or without diabetes.

Values refer to 87 (84.5%) diabetics and 410 (25.2%) non-diabetics.

| Characteristics                  | Diabetes N = 103 | No diabetes N = 1,629 | P      |
|----------------------------------|-----------------|----------------------|--------|
| Men, % (n)                       | 58.3 (60)       | 48.6 (792)           | 0.057  |
| Age, years                       | 64 (55.0–69.0)  | 51.0 (40.0–60.0)     | <0.001 |
| Body mass index, kg/m²           | 28.9 (25.3–33.3)| 25.5 (22.8–28.4)     | <0.001 |
| Waist circumference, cm          | 100 (92.0–108)  | 89.0 (80.0–96.0)     | <0.001 |
| Total cholesterol, mg/dL         | 348 (291–395)   | 331 (292–384)        | 0.318  |
| Triglycerides, mg/dL             | 189 (129–256)   | 106 (78.0–155)       | <0.001 |
| HDL cholesterol, mg/dL           | 47.5 (35.0–59.0)| 53.0 (45.0–64.0)     | <0.001 |
| LDL cholesterol, mg/dL           | 255 (202–312)   | 253 (211–300)        | 0.960  |
| HbA1c*, %                        | 6.7 (6.2–7.4)   | 5.5 (5.3–5.9)        | <0.001 |
| Tendon xanthomas, % (n)          | 32.0 (33)       | 28.7 (468)           | 0.487  |
| Positive genetic diagnosis, % (n)| 46.6 (48)       | 64.1 (1052)          | 0.005  |
| Cardiovascular disease, % (n)    | 40.8 (42)       | 51.0 (31.5–52.0)     | <0.001 |
| Hypertension, % (n)              | 64.1 (66)       | 16.7 (271)           | <0.001 |
| Age at diabetes diagnosis, years | 53.0 (48.0–60.0)| —                    | —      |
| Age at statin onset, years       | 51.5 (43.0–59.0)| 42.0 (31.5–52.0)     | <0.001 |
| Statin therapy, years            | 10.0 (6.0–17.0) | 7.0 (2.5–12.0)       | <0.001 |

Table 2. Demographic and clinical characteristics of heterozygous familial hypercholesterolemia patients with or without diabetes. *Values refer to 87 (84.5%) diabetics and 410 (25.2%) non-diabetics.

Besides this confirmatory information, several important conclusions can be drawn from our study. First, the LDL cholesterol concentration before the start of lipid-lowering treatment did not play a major role in T2DM protection in HeFH in our study. The lower risk of T2DM appeared in a large LDL cholesterol range, and the LDL cholesterol concentration before the start of lipid-lowering treatment did not play a major role in T2DM prevalence according to the presence or absence of causative gene mutations responsible for HeFH. Our study is the first to include clinically-diagnosed patients and analyzed T2DM prevalence according to LDLR, APOB or PCSK9 mutations. Besseling et al. included HeFH only with a confirmed pathogenic mutation, and found a dose-dependent association in HeFH subjects with LDLR negative mutations who had a lower T2DM prevalence than HeFH carriers of defective LDLR or APOB mutations, suggesting that the severity of the genetic defect plays a role in T2DM protection. The implication of the LDL receptor in glucose homeostasis is
controversial, since the deleterious effect of cholesterol overload on insulin secretion by pancreatic \( \beta \) cells was similar in LDLR-/- knockout or wild-type mice \(^{19} \), and oxidized LDL, which does not use the LDL receptor, was found to be a major contributor to \( \beta \) cell dysfunction \(^{20} \). Furthermore, some FH-causing mutations seem to be associated with a higher T2DM risk \(^{21} \). In our study, the presence of any LDLR/APOB/PCSK9 mutation was less common in HeFH with than without T2DM; however, these differences disappeared after adjustment for confounders unrelated to LDL receptor function.

Third, the factors associated with the presence of T2DM in HeFH are the same as those present in the general population, including statin use. The cluster of abnormalities closely associated with insulin resistance: high blood pressure, high triglycerides, low HDL cholesterol, increased BMI and older age \(^{46–48} \), are also strongly related to the presence of T2DM in HeFH, as previously described \(^{23} \). In this observational, cross-sectional study, we could not calculate whether the impact of T2DM risk factors is different in HeFH than in non-FH; however, we did have a close approximation for statin use as this information was available. Statin use preceded the diagnosis of T2DM in most cases and the risk associated with statin use was identical to that observed in statin trials after adjustment for insulin-resistance markers \(^{6, 7, 24} \).

Thus, if LDL cholesterol or LDL receptor function itself are not responsible for the T2DM protection in HeFH, which mechanisms are involved? Potential explanations have been previously put forward: the observational cross-sectional design without power to establish causality; the possibility of unexplored potential confounders; a healthier lifestyle after receiving the diagnosis of HeFH; or a shorter life-expectancy in patients with HeFH and 

|               | 18–45 years | 46–60 years | >60 years | Total        |
|---------------|-------------|-------------|-----------|--------------|
| Men General population, N/Total (%) | 14/909 (1.54) | 69/578 (11.9) | 163/687 (23.7) | 246/2174 (11.3) |
| HeFH, N/Total (%) | 2/337 (0.59) | 23/338 (6.80) | 35/178 (19.7) | 60/853 (7.03) |
| Odds ratio (95% CI) | 0.382 (0.086–1.688) | 0.538 (0.329–0.881) | 0.787 (0.523–1.185) | 0.593 (0.442–0.796) |
| P             | 0.261       | 0.012       | 0.272     | <0.001       |
| HeFH mutation+, N/Total (%) | 2/246 (0.81) | 15/188 (7.98) | 13/103 (12.6) | 30/537 (5.59) |
| Odds ratio (95% CI) | 0.524 (0.118–2.231) | 0.639 (0.356–1.147) | 0.478 (0.263–0.870) | 0.470 (0.319–0.694) |
| P             | 0.545       | 0.141       | 0.010     | <0.001       |

|               | 14/909 (1.54) | 54/818 (6.60) | 170/858 (19.8) | 233/2898 (8.04) |
| Women General population, N/Total (%) | 2/337 (0.59) | 18/318 (5.66) | 23/285 (8.07) | 43/880 (4.89) |
| Odds ratio (95% CI) | 0.980 (0.211–4.562) | 0.849 (0.489–1.471) | 0.355 (0.225–0.562) | 0.588 (0.421–0.821) |
| P             | 0.979       | 0.684       | <0.001     | 0.002        |
| HeFH mutation+, N/Total (%) | 2/221 (0.90) | 6/185 (3.24) | 10/157 (6.37) | 18/563 (3.20) |
| Odds ratio (95% CI) | 1.455 (0.359–5.093) | 0.508 (0.222–1.164) | 0.287 (0.150–0.549) | 0.387 (0.239–0.627) |
| P             | 0.597       | 0.087       | <0.001     | <0.001       |

|               | 23/2131 (1.08) | 123/1396 (8.81) | 333/1545 (21.6) | 479/5072 (9.44) |
| All General population, N/Total (%) | 4/614 (0.65) | 41/656 (6.25) | 58/463 (12.5) | 103/1733 (5.94) |
| Odds ratio (95% CI) | 0.601 (0.207–1.744) | 0.689 (0.478–0.995) | 0.521 (0.386–0.704) | 0.606 (0.486–0.755) |
| P             | 0.343       | 0.046       | <0.001     | <0.001       |
| HeFH mutation+, N/Total (%) | 4/467 (0.86) | 21/373 (5.63) | 23/260 (8.85) | 48/1100 (4.36) |
| Odds ratio (95% CI) | 0.791 (0.273–2.300) | 0.617 (0.383–0.995) | 0.353 (0.226–0.551) | 0.438 (0.323–0.593) |
| P             | 0.667       | 0.046       | <0.001     | <0.001       |

Table 3. Prevalence of type 2 diabetes in a reference population and in heterozygous familial hypercholesterolemia patients by sex and age.
T2DM could be responsible for this observation. The HDL particle is also an unexplored potential protective factor of T2DM in HeFH. In HeFH, HDL cholesterol is usually within normal range, and, in contrast with other dyslipidemias, HDL particle size and number are in antiatherogenic range. Indeed, the Dutch HeFH patients were leaner, smoked less and had lower triglycerides than their unaffected relatives without a clear explanation, except for a healthier lifestyle associated with the diagnosis. In our cohort of HeFH patients, the prevalence of hypertension, overweight, obesity and tobacco use was much lower than that observed in the Spanish general population. Altogether, these data suggest that environmental factors could be involved in this T2DM protection in these patients cared for in highly specialized lipid units. Actually, the reduction in BMI compared with the reference population could explain one third of the lower risk of T2DM. A large case-control study is underway to try to answer these questions.

Our study has some limitations. In this respect, the number of HeFH with T2DM was relatively low, but the concurrence with previous data supports the T2DM protection. Our study was cross-sectional, and results other than prevalence should thus be taken with caution. The sample was composed of middle-aged men and women from a Mediterranean country, with traditionally lower coronary heart disease rates than other populations, albeit with a high prevalence of T2DM. Furthermore, patients included in the Spanish Dyslipidemia Registry are treated with a standardized protocol promoting the use of high-intensity lipid-lowering treatment in highly

Table 4. Factors associated with the presence of type 2 diabetes mellitus in clinically-defined heterozygous familial hypercholesterolemia patients (≥ 6 DLCN points). DLCN denotes Dutch Lipid Clinic Network; BMI, body mass index. Independent variables included in the model: sex, age, BMI, smoking status, hypertension, tendon xanthomas, baseline LDL and HDL cholesterol and triglyceride concentrations, genetic diagnosis and statin therapy duration.

| Factor                      | Standard coeff. (β) | Exp (B)     | 95% CI        | p    | R²  |
|-----------------------------|---------------------|-------------|---------------|------|-----|
| Sex, male                   | 0.649               | 1.913       | 1.204–3.040   | 0.006|     |
| Age, years                  | 0.050               | 1.052       | 1.030–1.074   | <0.001|     |
| BMI, kg/m²                  | 0.021               | 1.021       | 1.007–1.035   | 0.004|     |
| Hypertension, yes           | 1.522               | 4.582       | 2.834–7.407   | <0.001|     |
| Triglycerides, mg/dL        | 0.002               | 1.002       | 1.001–1.003   | 0.001|     |
| Statin therapy, years       | 0.031               | 1.031       | 1.003–1.060   | 0.03  |     |

Table 5. Factors associated with the presence of type 2 diabetes mellitus in genetically-defined heterozygous familial hypercholesterolemia patients (with a pathogenic mutation in LDLR, APOB or PCSK9 genes). BMI denotes body mass index. Independent variables included in the model: sex, age, BMI, smoking status, hypertension, tendon xanthomas, baseline LDL and HDL cholesterol and triglyceride concentrations, genetic diagnosis and statin therapy duration.

| Factor                      | Standard coeff. (β) | Exp (B)     | 95% CI        | p    | R²  |
|-----------------------------|---------------------|-------------|---------------|------|-----|
| Sex, male                   | 0.713               | 2.041       | 1.081–3.853   | 0.028|     |
| BMI, kg/m²                  | 0.018               | 1.018       | 1.003–1.034   | 0.022|     |
| Hypertension, yes           | 2.072               | 7.942       | 4.249–14.845  | <0.001|     |
| Statin therapy, years       | 0.044               | 1.045       | 1.002–1.090   | 0.040|     |

Figure 2. Prevalence of type 2 diabetes mellitus in heterozygous familial hypercholesterolemic patients according to LDL-cholesterol concentrations.
specialized Lipid Clinics; thus, the results cannot be easily extrapolated to other clinical settings. Finally, the observed prevalence of T2DM in HeFH could be underestimated since patients with HeFH are at increased risk for cardiovascular disease and some will have died before their inclusion in the Dyslipidemia Spanish registry. If HeFH was associated with T2DM, the possibility of early death from cardiovascular causes was even higher. On the other hand, T2DM prevalence increases with age and HeFH patients who died prematurely might have been less likely to develop T2DM; thus, an overestimation of T2DM in our cohort is also possible. In any event, the mean age of HeFH patients was around 55 years, and the prevalence of T2DM increased with age in both HeFH patients and in the general population.

Conclusions

In summary, the absolute prevalence of T2DM in patients with HeFH was 40% lower than that observed in the general population matched for age and sex. Risk factors independently associated with the presence of T2DM in subjects with HeFH were age, male sex, BMI, baseline triglycerides, and years of statin treatment. LDL cholesterol concentrations and the presence of mutations in FH-causing genes were not associated with the presence of T2DM in HeFH subjects.

Table 6. Effect of phenotype severity in heterozygous familial hypercholesterolemia on type 2 diabetes prevalence. 'Adjusted for age, sex and years of statin use. †Adjusted for age, sex, years of statin use and body mass index. ‡Adjusted for age, sex, years of statin use, body mass index, triglycerides, and hypertension.

| Comparison | All | HeFH with LDL < 250 mg/dL | HeFH with LDL ≥ 250 mg/dL | HeFH with > 8 points |
|------------|-----|----------------------------|---------------------------|---------------------|
| Odds ratio (95% CI) Unadjusted | 0.821 (0.429–1.572) | 0.736 (0.287–1.887) | 2.384 (0.557–10.207) | 0.707 (0.294–1.696) |
| Odds ratio (95% CI) Adjusted† | 0.954 (0.488–1.866) | 1.386 (0.498–3.852) | 2.395 (0.549–10.444) | 0.747 (0.303–1.839) |
| Odds ratio (95% CI) Adjusted‡ | 0.836 (0.478–1.835) | 1.388 (0.496–3.887) | 2.806 (0.631–12.478) | 0.735 (0.288–1.813) |
| Odds ratio (95% CI) Adjusted‡ | 1.072 (0.533–2.155) | 1.474 (0.512–4.243) | 3.056 (0.670–13.930) | 0.877 (0.341–2.250) |

References

1. Hovingh, G. K., Davidson, M. H., Kastelein, J. J. & O’Connor, A. M. Diagnosis and treatment of familial hypercholesterolaemia. Eur. Heart J. 34, 962–971 (2013).
2. Carnarros, A. et al. The p.Leu167del mutation in APOE gene causes autosomal dominant hypercholesterolemia by down-regulation of LDL receptor expression in hepatocytes. J. Clin. Endocrinol. Metab. 101, 2113–2121 (2016).
3. Vohl, M. C. et al. Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia. Eur. J. Clin. Invest. 27, 366–373 (1997).
4. Besseling, J., Kastelein, J. J., Defesche, J. C., Hutten, B. A. & Hovingh, G. K. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 313, 1029–1036 (2015).
5. Preiss, D. & Sattar, N. Does the LDL receptor play a role in the risk of developing type 2 diabetes? JAMA. 313, 1016–1017 (2015).
6. Sattar, N. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 375, 735–742 (2010).
7. Preiss, D. et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 305, 2556–2564 (2011).
8. Katsiki, N., Rizzo, M., Mikhailidis, D. P. & Mantzoros, C. S. New-onset diabetes and statins: throw the bath water out, but, please, keep the baby! Metabolism. 64, 471–475 (2015).
9. Miller, P. E. & Martin, S. S. Approach to statin use in 2016: an update. Curr. Atheroscler. Rep. 18, 20 (2016).
10. Nordestgaard, B. G. Approach to statin use in 2016: an update. Scientific Reports | 7: 5596 | DOI:10.1038/s41598-017-06101-6

7

www.nature.com/scientificreports/
24. Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P. & Glynn, R. J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 380, 565–571 (2012).
25. von Eckardstein, A. & Sibler, R. A. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr. Opin. Lipidol. 22, 26–32 (2011).
26. Civeira, F. et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Ann. J. Cardiol. 102, 1187–1193 (2008).
27. Jarauta, E. et al. Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolemia and familial combined hyperlipidemia. Nutr. Metab. Cardiovasc. Dis. 22, 591–597 (2012).
28. Grau, M. et al. Cardiovascular risk factors in Spain in the first decade of the 21st century, a pooled analysis with individual data from 11 population-based studies: The DARIOS Study. Rev. Esp. Cardiol. 64, 295–304 (2011).
29. Garcia-Esquinas, E. et al. Obesity, fat distribution, and risk of frailty in two population-based cohorts of older adults in Spain. Obesity (Silver Spring) 23, 847–55 (2015).
30. Vazquez, G., Duval, S., Jacobs, D. R. & Silventoinen, K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiol. Rev. 29, 115–28 (2007).

Acknowledgements
We thank the Lipid Units for inclusion of cases in the Dyslipidemia Registry of the Spanish Arteriosclerosis Society, and Miss Christine O’Hara for review of the English version of the manuscript. CIBEROBN is an initiative of ISCIII, Spain. S. Perez-Calahorra: grants from Amgen, Sanofi and Pfizer. E. Ros has received lecture honoraria, consultancy fees and/or research funding from Aegerion, Alexion, MSD, Pfizer and Sanofi. F. Civeira: grants, consulting fees, and/or honoraria from Amgen, Merck, Pfizer, and Sanofi-Aventis. J. Pedro-Botet has received lecture honoraria, consultancy fees and/or research funding from Astra-Zeneca, Esteve, Merck, Mylan and Sanofi-Aventis.

Author Contributions
E.C.: acquisition, analysis, and interpretation of data for the work; drafting the work; S.P.-C.: acquisition and statistical analysis of data. V.M.-B.: analysis and interpretation of data for the work. N.P.: interpretation of data for the work, revising it critically. R.S.: acquisition and statistical analysis of data. E.R.: interpretation of data for the work, revising it critically. J.F.A.: conception and design of the work; analysis and interpretation of data for the work; drafting the work. All authors have read and approved the final manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-06101-6

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017